ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
The role of SBRT as an ablative treatment in oligometastatic patients.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtracranial oligometastatic disease, defined as up to five metastases, represents an intermediate cancer state with potential for long-term control. Stereotactic body radiotherapy (SBRT) is a non-invasive treatment associated with high local control, limited toxicity, and the ability to delay systemic therapy. This study reports institutional outcomes of SBRT across oligometastatic scenarios. MATERIALS AND
methodsWe retrospectively analyzed 259 patients with 401 extracranial oligometastatic lesions from solid tumors treated with SBRT between 2016 and 2022. Patients were classified according to the ESTRO-EORTC consensus as oligorecurrence, oligoprogression, or oligopersistence, and as synchronous or metachronous. The eligibility criteria included ECOG 0-1, life expectancy > 6 months, ≤ 5 treatment-naïve extracranial metastases, and no intracranial disease. Survival outcomes were estimated using the Kaplan-Meier method.
resultsAfter a median follow-up of 68.7 months, SBRT achieved durable local control exceeding 80% beyond 4 years across all metastatic sites, with lung and lymph node lesions showing the best outcomes. Overall disease control declined due to new metastases; however, over 40% of lesions remained progression-free at 6 years. Superior outcomes were observed in patients with genuine oligometastatic disease, de novo or synchronous presentation, and fewer treated lesions. Median overall survival (OS) was 93.8 months (95%CI 81.1-106.4) and was longer in patients with initially locoregional disease and prostate cancer.
conclusionsIn this retrospective single-center experience, SBRT achieved durable local control with acceptable toxicity in selected patients with extracranial oligometastatic disease. These findings are consistent with previously published series and support the role of SBRT as a metastasis-directed approach in carefully selected patients. Prospective studies are needed to better define prognostic subgroups and optimize patient selection.
Indexed as
Identifiers
42322556What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.